NCT01079949 / 2006-005268-19: A Phase II Study to Assess the Efficacy and Safety of Luveris® (Lutropin Alfa) in Mid Follicular Phase for Controlled Ovarian Stimulation (COS) in Advanced Reproductive Age |
|
|
| Terminated | 2 | 93 | Europe | r-hLH + r-hFSH, Luveris®, Lutropin alfa, r-hFSH, Recombinant Human Choriogonadotropin (r-hCG), Ovitrelle®, GnRH antagonist, Cetrotide® | Merck KGaA, Darmstadt, Germany, Merck, S.L., Spain | Infertility, Ovulation Induction | 10/10 | 10/10 | | |
2022-000753-80: Clinical research study to learn about the effect and safety of different doses of FE 999302 when given as a single dose for final development of the eggs after ovarian stimulation Estudio de investigación clínica para conocer el efecto y la seguridad de diferentes dosis de FE 999302 cuando se administra como dosis única para el desarrollo final de los óvulos después de la estimulación ovárica |
|
|
| Ongoing | 2 | 500 | Europe | NOVAREL, OVITRELLE, FE 999302, FE 999086, Solution for injection, Powder and solvent for solution for injection, Solution for injection in pre-filled pen, Solution for injection in pre-filled syringe, NOVAREL, OVITRELLE | Ferring Pharmaceuticals A/S, Ferring Pharmaceuticals A(S | Infertility Infertilidad, Infertility Infertilidad, Body processes [G] - Reproductive physiologi cal processes [G08] | | | | |
TIFFANY, NCT05571111: Clinical Research Study to Learn About the Effect and Safety of Different Doses of FE 999302 When Given as a Single Dose for Final Development of the Eggs After Ovarian Stimulation |
|
|
| Withdrawn | 2 | 0 | Europe | FE 999302, recombinant hCG, Ovitrelle, Novarel | Ferring Pharmaceuticals | Infertility | 03/24 | 06/24 | | |
